Biopharma | June 04, 2025
Sanofi exercises license extension option to Nurix’s STAT6 program
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Standalone profit from operations for the quarter were Rs. 162 crores
The Q1 2025 also witnessed a successful launch of Allegra D
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
No safety signals related to the vaccine candidate were identified
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Subscribe To Our Newsletter & Stay Updated
